In Research News

Whether mobiles phones cause brain cancer has been a subject of ongoing debate, but a new study is suggesting that they don’t.

A 30-year examination of the incidence of brain tumours in Scandinavia found no substantial change in prevalence even after cell phone use became widespread, according to the report in the Dec. 3 online edition of the Journal of the National Cancer Institute.

“If mobile phones were to cause brain tumors we would expect to see a sudden rise in the number of brain tumors at some point in time, and we don’t see it,” said lead researcher Isabelle Deltour, from the Institute of Cancer Epidemiology at the Danish Cancer Society in Copenhagen.

However, Deltour does leave the door open to the possibility that widespread cell phone use hasn’t been around long enough to see an increase in brain tumors. “Either it means that mobile phones don’t cause brain tumors or it means that we don’t see it yet or we don’t see it because the increase is too small to be observed in this population, or it is a risk that is limited to a small subgroup of the population,” she said.

Deltour’s team will continue to look at the rates of brain tumors in the study group, she added. For the study, Deltour’s team collected data on 60,000 people diagnosed with glioma and meningioma in Denmark, Finland, Norway and Sweden between 1974 and 2003. The researchers found that the incidence of brain tumours over this 30-year period were stable, decreased or gradually increased, starting before cell phones became popular.

In addition, there was no change in the incidence of brain tumors between 1998 and 2003, during a period of rapid increase in cell phone usage, the researchers noted.

Dr. Paul Graham Fisher, an associate professor of neurology, pediatrics, and neurosurgery and human biology and the Beirne Family Director of Neuro-Oncology at Stanford University (USA), said that “this topic won’t go away.” Fisher thinks that like so many irrational fears, such as harm from radiation from electric wires, the connection between cell phones and brain tumors will persist even though there is no scientific evidence for such a connection.

“This is sort of the high-tension wires of our time,” Fisher said. “This is an issue that is probably not going to go away, because people have this suspicion and it’s fueled by some public paranoia and by people who make very provocative statements, and that is enough to make it not go away, despite very good science.”

However, a review of existing research on the topic, published online Oct. 13 in the Journal of Clinical Oncology, did find a slight, potentially harmful association between cell phone use and brain tumors. Commenting on that study, Dr. Deepa Subramaniam, director of the Brain Tumor Center at Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C., said at the time that “we cannot make any definitive conclusions about this. But this study, in addition to all the previous studies, continues to leave lingering doubt as to the potential for increased risk. So, one more time, after all these years, we don’t have a clear-cut answer.”

It looks as though this one might rumble on for a while, but even if a link is proven, will people stop using their mobiles? We’ll be watching this one closely, and any views you might have, let us know at will@brainstrust.org.uk

What an amazing man.Charity News
Intraoperative MRI scanning reaches Alder Hey HospitalCharity News

Introduction

The Brain Tumour Data Dashboard lets you explore up -to-date, population level data about the brain tumours diagnosed in England between 2013 and 2015. Using the drop down menus on the left you can select different groups of patients to view in the charts below. In these charts the number of patients for every 100 diagnoses is displayed as images of people. Patients have been grouped by date of diagnosis, type of tumour, age, gender, and region in England.

For each group of patients you can explore the different routes to diagnosis, the proportion of those who received chemotherapy or radiotherapy, as well as the survival of the patients within each group. For more information about what these metrics mean please see the glossary.

How to use

  1. Select the year of diagnosis using the drop down menu.
  2. Select your patient group of interest from the four drop down menus in the following order:
    1. Tumour group
    2. Age at diagnosis
    3. Region of England
    4. Gender of patient
  3. To view a second chart to compare different groups of patients, click the ‘compare’ button.The second chart will appear below the first chart.

*Note that the tool is best used on a laptop or tablet rather than a mobile phone*

Unavailable data

Some of the data in these charts is not available.There are two main reasons for this:

  1. How the data has been grouped

If you cannot select a patient group from the drop down menus, the data is unavailable because of how the data has been organised.

Public Health England has grouped the data like a branching tree. The bottom of the tree contains all the patients with brain tumours, and then each branch divides the data by a certain characteristics, like age, or location of tumour. But the data is divided in an order, starting with location of the tumour (endocrine or brain), then by age, region, and gender. Age is at the start because it makes a bigger difference to survival rates and treatment rates than gender or region. Sometimes, after the data has been split by type of tumour and age, there is not enough data to be split again. This is because to protect patient confidentiality groups cannot contain less than 100 patients. Because some groups cannot be split further, you cannot create ‘totals’ for everyone by region or gender. For example, you cannot see results for all ages by region, or all brain tumours by gender. If these totals were calculated and released, it might be possible to identify patients, which is why Public Health England cannot release this data.

  1. Statistical reasons and data availability

If you can select a patient group from the chart menus, but the chart does not display, the data is unavailable for one of several reasons:

  1. Data is not yet available for the selected year from Public Health England.
  2. Data is not available because the data quality is too poor to release this statistic.
  3. Data is not available as the statistic is not appropriate for this group.
  4. Data is not available because the standard error of the estimate was greater than 20% and so the estimate has been supressed.

Up to date brain tumour data

Brain tumour data may influence the decisions you make about your care. Data also helps you understand the bigger picture, or landscape, in which you find yourself.

Brain tumour data and statistics influence the focus, and work of organisations like brainstrust. The information helps us to understand the scale and impact of the problems we are setting out to solve.

This tool helps you understand the landscape in which you find yourself having been diagnosed with a brain tumour. This landscape can be particularly tricky to navigate as there are many different types of brain tumour, all of which have a different impact.

The information you see represents the most up-to-date, official, population level brain tumour data available for England. Over time we will be adding to the brain tumour data available and publishing reports, with recommendations, as a result of what we learn from this data.

The data behind this content has come from Public Health England’s National Cancer Registration and Analysis Service (NCRAS) and is a direct result of the ‘Get Data Out’ project.

This project provides anonymised population level brain tumour data for public use in the form of standard output tables, accessible here: http://cancerdata.nhs.uk/standardoutput

Incidence

The number or rate (per head of population) of new cases of a disease diagnosed in a given population during a specified time period (usually a calendar year). The crude rate is the total number of cases divided by the mid-year population, usually expressed per 100,000 population.

Malignant

Malignant tumours which grow by invasion into surrounding tissues and have the ability to metastasise to distant sites

Mortality

The number or rate (per head of population) of deaths in a given population during a specified time period (usually a calendar year). The crude rate is the total number of deaths divided by the mid-year population, usually expressed per 100,000 population.

Non-malignant

Not cancerous. Non-malignant tumours may grow larger but do not spread to other parts of the body.

Survival

The length of time from the date of diagnosis for a disease, such as cancer, that patients diagnosed with the disease are still alive. In a clinical trial, measuring the survival is one way to see how well a new treatment works. Also called ‘overall survival’ or ‘OS’.

Routes to Diagnosis

Under the ‘Routes to Diagnosis’ tab in the Brain Tumour Data Dashboard, you can explore the ways patients have been diagnosed with brain tumours. There are many ways, or routes, for cancers to be diagnosed in the NHS. A ‘route to diagnosis’ is the series of events between a patient and the healthcare system that leads to a diagnosis of cancer. The routes include:

  1. Two Week Wait

Patients are urgently referred by their GP for suspected cancer via the Two Week Wait system and are seen by a specialist within 2 weeks where they are diagnosed.

  1. GP referral

Diagnosis via a GP referral includes routine and urgent referrals where the patient was not referred under the Two Week Wait system.

  1. Emergency Presentation

Cancers can be diagnosed via emergency situations such as via A&E, emergency GP referral, emergency transfer or emergency admission.

  1. Outpatient

Outpatient cancer diagnoses include diagnoses via an elective route which started with an outpatient appointment that is either a self-referral or consultant to consultant referral. (It does not include those under the Two Week Wait referral system).

  1. Inpatient elective

Diagnosis via an inpatient elective route is where diagnosis occurs after the patient has been admitted into secondary care from a waiting list, or where the admission is booked or planned.

  1. Death Certificate Only

Diagnoses made by Death Certificate Only are made where there is no more information about the cancer diagnosis other than the cancer related death notifications. The date of diagnosis is the same as that of the date of death.

  1. Unknown

For some patients with a cancer diagnosis, there is no relevant data available to understand the route to diagnosis.

 

More information

If any of the statistical terms in this section of the brainstrust website are hard to understand, we recommend looking them up here:

Cancer Research UK’s Cancer Statistics Explained

http://www.cancerresearchuk.org/health-professional/cancer-statistics/cancer-stats-explained/statistics-terminology-explained#heading-Seven

If you are looking for help understanding terms relating specifically to brain tumours, and treatment, then the brainstrust glossary is available here:

https://www.brainstrust.org.uk/advice-glossary.php